Marco Taglietti, Scynexis CEO

Scynex­is builds out case for its an­ti­fun­gal in the hos­pi­tal­ized set­ting, but in­vestors don't seem hap­py

The an­ti­fun­gal work at Scynex­is is not abat­ing. Look­ing to ex­pand be­yond its ini­tial June 2021 nod for treat­ing vagi­nal yeast in­fec­tion, the biotech has new da­ta on oral ibrex­a­fungerp for hos­pi­tal­ized pa­tients with dif­fi­cult-to-treat and re­frac­to­ry fun­gal in­fec­tions.

The New Jer­sey biotech said da­ta from 47 new­ly evalu­able pa­tients across two Phase III tri­als of the drug, the fourth in­ter­im analy­sis out of the stud­ies, showed oral ibrex­a­fungerp’s po­ten­tial in fill­ing a “sig­nif­i­cant need for a new an­ti­fun­gal ther­a­py,” ac­cord­ing to med­ical chief David An­gu­lo. But in­vestors thought dif­fer­ent­ly and sent shares $SCYX tum­bling 20% af­ter the open­ing bell Fri­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.